ABIONYX Pharma Provides an Update on Its Business and Cash Position for the Third Quarter of 2024
14 Novembre 2024 - 7:00PM
Business Wire
- Consolidated revenue of €3.4m at the end of September
2024
- Cash position of €4.1m before receipt of IRIS Pharma’s CIR
(€610k) as of September 30, 2024
- Live broadcast of the General Meeting on November 28, 2024,
at 2.00 pm CET
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA
PME), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the
recombinant human apolipoprotein apoA-I, today provides an update
on its business and its cash position as of September 30, 2024.
Selected financial information (IFRS)
€m
Q3 2024
Q3 2023
Revenue from biotech activity
0.00
0.00
Revenue from IRIS Pharma
3.41
3.60
Total revenue
3.41
3.60
Other revenue income and
revenue
0.00
0.00
Total revenue income and
revenue
3.41
3.60
Cash and cash equivalents at the end of
the period
4.06
1.70
ABIONYX Pharma recorded consolidated a quarterly revenue of
€3.41m for the third quarter of 2024, as no studies were
commissioned from IRIS Pharma during this quarter. With regard to
the discovery and development of innovative therapies designed to
improve patients' lives, the Company did not generate any revenue
in this quarter, as ABIONYX Pharma continues to provide its
bioproduct free of charge as part of its compassionate access
applications.
As of September 30, 2024, the Company's cash position reached
€4.1m, before the reimbursement of Iris Pharma’s CIR (€0.6m).
The Company reminds that a Combined General Meeting (Ordinary
and Extraordinary) will be held on November 28, 2024 at 2 pm CET,
the main resolutions proposed of which will concern the appointment
of three new directors, the facilitation of the Company's
development and shareholder loyalty in order to take advantage of
the opportunities introduced by law no. 2024-537 of June 13, 2024,
aimed at boosting company financing and the attractiveness of
France.
Shareholders wishing to follow the General Meeting but unable to
attend in person are invited to log on to the following link:
https://app.livestorm.co/newcap-1/retransmission-en-direct-de-lassemblee-generale-mixte-dabionyx-le-28-novembre-2024?type=detailed
As a reminder, will not allow remote voting or questions.
Further information on this General Meeting, and in particular on
shareholder voting procedures, is available at www.abionyx.com.
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on
developing innovative medicines for diseases where there is no
effective or existing treatment, even the rarest ones. The company
expedites the development of novel therapeutics through an
extensive expertise in lipid science and a differentiated
apoA-I-based technology platform. ABIONYX Pharma is committed to
radically improving treatment outcomes in Sepsis and critical
care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241114761381/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
